Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Gastroenterol ; 93(12): 2469-75, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9860411

ABSTRACT

OBJECTIVE: The severity of hepatic abnormalities and extent of dysfunction of other organ systems influences prognosis for cirrhosis. The Child-Pugh system has been used to classify cirrhotic patients into good, intermediate, or poor risk categories in evaluation and therapy. Disregard for cardiorespiratory, renal, electrolyte balance, and acid base status limits its predictive accuracy. We evaluated the accuracy of Acute Physiology and Chronic Health Evaluation (APACHE III) to predict short term hospital mortality in patients with liver cirrhosis. METHODS: A total of 282 patients were prospectively enrolled. Child-Pugh and APACHE III scores were recorded on day 1 for each patient. RESULTS: Mean age was 51.7+/-11.3 yr, with 65% men and 35% women; 57% presented with upper GI bleeding, 47% encephalopathy, 9% hepatorenal syndrome, and 7% hepatocellular carcinoma. Sixty-three patients (22%) died. Major causes of death were upper GI bleeding 38%, liver failure 21%, hepatorenal syndrome 19%, hepatocellular carcinoma 4%, and spontaneous bacterial peritonitis 6%. Child-Pugh and APACHE III scores for survivors (8.6+/-2.3 and 58.9+/-35.1) were lower than those for nonsurvivors (10.9+/-2.7 and 87.4+/-30.3) (p < 0.001). Using discriminant analysis, APACHE III correctly identified 75% of cases vs 67% of cases for Child-Pugh (p < 0.05). When information regarding ascites and prothrombin time was added to APACHE III, 81% of cases were correctly classified. CONCLUSION: The APACHE III scoring system is superior to Child-Pugh for prognosticating short term survival of cirrhotic patients. Prognostic accuracy of APACHE III can be enhanced by incorporating information regarding ascites and prothrombin time prolongation.


Subject(s)
Hospital Mortality , Liver Cirrhosis/mortality , APACHE , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Discriminant Analysis , Evaluation Studies as Topic , Female , Forecasting , Humans , Male , Middle Aged , Severity of Illness Index
2.
J Pak Med Assoc ; 48(7): 192-6, 1998 Jul.
Article in English | MEDLINE | ID: mdl-10067020

ABSTRACT

OBJECTIVE: A prospective randomized trial was conducted to compare efficacy, safety and complications of band ligation (BL) with sclerotherapy (Scl). METHODS: Patients with esophageal variceal bleeding were randomized into two study groups. BL (group A) was done in 28 patients whereas 30 patients (group B) had Scl. After initial treatment, follow-up sessions were repeated by the same method every two weeks till obliteration or reduction to grade 1. Subsequent sessions of endoscopy were done every three months, same procedure was repeated for recurrence of varices and for any episode of rebleeding. RESULTS: Initial control of bleeding by Scl was achieved in 22 of 28 patients (78%) and in 23 of 24 patients (96%) with BL. Eradication of varices was significantly better achieved in BL group, with less treatment sessions required in Group A as compared with group B 2 +/- 1.2 vs 5 +/- 2.5, P < 0.001). Major complications (3% vs 16%, P < 0.05) as well as mortality (11% vs 21%, P > 0.05) was higher in group B. CONCLUSION: Band ligation was more effective mode of treatment and was associated with lesser early mortality and complications as compared with sclerotherapy.


Subject(s)
Esophageal and Gastric Varices/surgery , Esophagoscopy , Sclerotherapy , Endoscopy/adverse effects , Endoscopy/methods , Esophageal and Gastric Varices/therapy , Female , Follow-Up Studies , Gastrointestinal Hemorrhage/surgery , Gastrointestinal Hemorrhage/therapy , Humans , Ligation/adverse effects , Ligation/methods , Male , Middle Aged , Prospective Studies , Recurrence , Reoperation , Retreatment , Safety , Sclerosing Solutions/administration & dosage , Sclerosing Solutions/therapeutic use , Sclerotherapy/adverse effects , Sclerotherapy/methods , Survival Rate
3.
J Pak Med Assoc ; 48(7): 197-201, 1998 Jul.
Article in English | MEDLINE | ID: mdl-10067022

ABSTRACT

Hepatocellular carcinoma is one of the most common malignancies world wide. We present data on 76 patients admitted to the Shaikh Zayed Hospital. Mean age was 52.2 +/- 11.3 years. Eighty six percent were males and 14% females. Eighty-six percent patients had underlying cirrhosis documented on ultrasound examination. Seventy-five percent were positive for anti HCV, 10% for HBsAg positive, 10% for both HBsAg and anti HCV and 5% cases had negative viral serology. Main clinical features were abdominal pain, weight loss, jaundice, hepatomegaly and ascites. Forty-three percent patients were Child-Pugh class A, 30% class B and 13% class C and 14% were non cirrhotic. Mean alfa fetoprotein levels were 142 +/- 155 ng/ml (range 2.7 to 1470). Diagnosis of hepatocellular carcinoma was established in 60 patients by fine needle aspiration biopsy under ultrasound guidance. Two patients died after biopsy due to uncontrollable bleeding. Fifty-four percent patients had a solitary lesion and 46% had multifocal or diffuse lesions. The average size of lesion was 7.8 x 8.1 cm. Twenty-two patients received intralesional alcohol injection. Fifty-four percent of these with a tumor size greater than 8 cm died during follow up. The major cause of death was liver failure in 8 patients and fatal bleeding occurred in 4 patients. Hepatocellular carcinoma has a high prevalence in middle aged males with a strong association with anti HCV positive cirrhosis. Patients with a tumour size greater than 8 cm have a poor response to intralesional alcohol injection.


Subject(s)
Carcinoma, Hepatocellular/diagnosis , Liver Neoplasms/diagnosis , Abdominal Pain/diagnosis , Adolescent , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Ascites/diagnosis , Biopsy, Needle , Carcinoma, Hepatocellular/pathology , Cause of Death , Ethanol/administration & dosage , Ethanol/therapeutic use , Female , Hemorrhage/etiology , Hepatitis B/diagnosis , Hepatitis C/diagnosis , Hepatomegaly/diagnosis , Humans , Injections, Intralesional , Jaundice/diagnosis , Liver Cirrhosis/classification , Liver Cirrhosis/diagnostic imaging , Liver Failure/etiology , Liver Neoplasms/pathology , Male , Middle Aged , Survival Rate , Ultrasonography, Interventional , Weight Loss , alpha-Fetoproteins/analysis
SELECTION OF CITATIONS
SEARCH DETAIL